FDA Brief

Warning letters Drugs

FDA warning letter to

Lumimeds

High riskIssued Sep 9, 2025Posted Sep 16, 2025Center for Drug Evaluation and Research (CDER)

FDA warns Lumimeds over website claims implying its compounded semaglutide and tirzepatide are FDA-approved.

What happened

FDA reviewed the website at https://lumimeds.com in August 2025 and observed that it offers compounded drug products, including semaglutide and tirzepatide. FDA found that website claims suggesting these compounded products were the same as FDA-approved brand-name medicines, including a statement that GLP-1 was FDA-approved for weight loss, were false or misleading because compounded drugs are not FDA-approved.

What FDA found

  1. FDA says the website's claims were false or misleading because they suggested the compounded semaglutide and tirzepatide were the same as FDA-approved brand-name drugs, when compounded drugs are not FDA-approved.

    FDCA sections 502(a) and 502(bb) [21 U.S.C. §§ 352(a) and 352(bb)]
  2. FDA says a website statement that GLP-1 was FDA-approved in 2017 and 2021 for weight loss misleads consumers about the approval status of Lumimeds' compounded products.

    FDCA sections 502(a) and 502(bb) [21 U.S.C. §§ 352(a) and 352(bb)]
  3. FDA says shipping these misbranded drugs across state lines is a prohibited act.

    FDCA section 301(a) [21 U.S.C. § 331(a)]
  4. FDA says receiving misbranded drugs in interstate commerce and delivering or offering to deliver them is also prohibited.

    FDCA section 301(c) [21 U.S.C. § 331(c)]

What FDA wants

FDA tells Lumimeds to take immediate action, including ceasing use of the cited language, and to send CDER's Office of Compounding Quality and Compliance a written response within 15 working days describing steps taken and how recurrence will be prevented, with supporting documents.

Who should pay attention

  • telehealth companies selling compounded GLP-1 drugs
  • online pharmacies and compounding pharmacies marketing semaglutide or tirzepatide
  • platforms or brands that host or promote compounded drug claims

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. New Green Nutrition Inc.

    FDA says New Green Nutrition sold unapproved drugs online, and its Qu Feng Huo Luo Dan contained hidden dexamethasone.

    High risk
  2. Ong Tien USA LLC

    FDA warned Ong Tien USA LLC that its herbal joint products are unapproved drugs and one contained hidden piroxicam and dexamethasone.

    High risk
  3. Bella’s Nutri Shop Inc.

    Bella’s Nutri Shop sells “Tawon Liar” as an unapproved drug with hidden dexamethasone, tapentadol, and meloxicam.

    High risk
  4. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low